sglt2 glp-1 news GLP1 Receptor Agonists vs SGLT2-I in Preventing CKD in T2DM: An Interview – AJKD Blog Diabetic Agents, From Metformin to

Insurer claims nearly doubled in 2024 The financial footprint of GLP-1 medications in Canada helps explain the market's scale

Tissue perfusion and sexual function pathways A case report of female anorgasmia and hypoarousal temporally related to GLP-1 agonist use (including semaglutide after a switch from liraglutide) proposed mechanisms including smooth-muscle vasoconstriction with reduced genital blood flow and central neurotransmitter pathway effects (hypothalamic signalling)

Visual inspection alone isn't enough if you're serious about efficacy

That's a meaningfully different pharmacological premise than most injectable peptides, and it's the reason BPC-157 is one of relatively few peptides studied mostly in animal models as an oral candidate at all

A doctor can also guide you on the type of treatment that would be most effective for you

This microenvironment was characterised by an 80% increase in adipocyte nuclei, larger adipocytes and activation of gene sets associated with adipogenesis including IGF-1 (Kang et al., 2020)